MITHRIDATE: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera

Trial Overview and Summary

Chief Investigator: Professor Claire Harrison
Sponsor: University of Birmingham
Funders: Novartis, MPN Voice and INCa (the French National Cancer Institute)
Disease Site: Haematology
Trial Type: Clinical Trial of Investigational Medicinal Products
Status: Open
UKCRN Study ID: (if applicable) 39201
Open to new sites? Yes
Recruitment start date: 25th October 2019
Anticipated Recruitment end date  
CRCTU Trial Management Team: B Team
Trial E-mail Address: 

Trial Summary

The MITHRIDATE study has been set up to investigate which treatment is most effective for patients who have high risk polycythemia vera (PV). The study will test how safe and effective a drug called ruxolitinib is when treating patients with PV compared to the current Best Available Therapy (BAT).

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.

Trial Protocol

Please note: Clinical trial protocols are complex technical documents, which should only be used for the treatment of subjects taking part in the trial.  Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to  the Cancer Research UK website 

To view the Protocol and other trial related documents, please refer to the Investigators page.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.